{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:09Z","timestamp":1793502729540,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Health"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA180803"],"award-info":[{"award-number":["U24CA180803"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Clinical Trials Network","award":["U10CA180886"],"award-info":[{"award-number":["U10CA180886"]}],"id":[{"id":"https:\/\/ror.org\/01a2yyy59","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Clinical Trials Network","award":["U10CA180899"],"award-info":[{"award-number":["U10CA180899"]}],"id":[{"id":"https:\/\/ror.org\/01a2yyy59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"St. Baldrick\u2019s Foundation Consortium Grant","id":[{"id":"https:\/\/ror.org\/03h1gea69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A phase I\/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children\u2019s Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Vorinostat was given once daily, Monday through Friday, during radiation therapy (54 Gy in 30 fractions), and then continued at 230 mg\/m2 daily for a maximum of twelve 28-day cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve patients enrolled in the phase I study; the RP2D of vorinostat given concurrently with radiation was 230 mg\/m2\/day, Monday through Friday weekly. The six patients enrolled at the RP2D and an additional 64 patients enrolled in the phase II study contributed to the efficacy assessment. Although vorinostat was well-tolerated, did not interrupt radiation therapy, and was permanently discontinued in only 8.6% of patients due to toxicities, risk for EFS-event was not significantly reduced compared with the target risk derived from historical COG data (P = 0.32; 1-sided). The 1-year EFS was 5.85% (95% CI 1.89\u201313.1%) and 1-year OS was 39.2% (27.8\u201350.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vorinostat given concurrently with radiation followed by vorinostat monotherapy was well tolerated in children with newly diagnosed DIPG but failed to improve outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noab188","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T07:19:18Z","timestamp":1627975158000},"page":"655-664","source":"Crossref","is-referenced-by-count":61,"title":["Phase I\/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children\u2019s Oncology Group report"],"prefix":"10.1093","volume":"24","author":[{"given":"Jack M","family":"Su","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay B","family":"Kilburn","sequence":"additional","affiliation":[{"name":"Center for Cancer & Blood Disorders, Children\u2019s National Medical Center, Washington DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Mansur","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rainbow Babies and Children\u2019s Hospital, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[{"name":"Department of Statistics, Children\u2019s Oncology Group, Monrovia, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Buxton","sequence":"additional","affiliation":[{"name":"Department of Statistics, Children\u2019s Oncology Group, Monrovia, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adesina","family":"Adekunle","sequence":"additional","affiliation":[{"name":"Department of Pathology, Texas Children\u2019s Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Adamson","sequence":"additional","affiliation":[{"name":"Global Head, Oncology Development, Sanofi, Cambridge, Massachussetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hem\/Onc\/BMT, University of Minnesota\/Masonic Cancer Center, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Blaney","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-035X","authenticated-orcid":false,"given":"Maryam","family":"Fouladi","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Program, Nationwide Children\u2019s Hospital, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"3","key":"2022040109570001600_CIT0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","article-title":"Diffuse brainstem glioma in children: critical review of clinical trials","volume":"7","author":"Hargrave","year":"2006","journal-title":"Lancet Oncol."},{"issue":"19","key":"2022040109570001600_CIT0002","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and european society for pediatric oncology DIPG registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022040109570001600_CIT0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/neuonc\/noq202","article-title":"Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas","volume":"13","author":"Haas-Kogan","year":"2011","journal-title":"Neuro Oncol."},{"issue":"3","key":"2022040109570001600_CIT0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/neuonc\/noq191","article-title":"Temozolomide in the treatment of high-grade gliomas in children: a report from the children\u2019s oncology group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol."},{"issue":"4","key":"2022040109570001600_CIT0005","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/1097-0142(19930815)72:4<1404::AID-CNCR2820720441>3.0.CO;2-G","article-title":"Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A phase II study of the pediatric oncology group, protocol 8833","volume":"72","author":"Kretschmar","year":"1993","journal-title":"Cancer."},{"issue":"10","key":"2022040109570001600_CIT0006","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>3.0.CO;2-T","article-title":"Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I\/II study","volume":"77","author":"Packer","year":"1996","journal-title":"Cancer."},{"issue":"1","key":"2022040109570001600_CIT0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1096-911X(199801)30:1<28::AID-MPO9>3.0.CO;2-2","article-title":"Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I\/II study","volume":"30","author":"Walter","year":"1998","journal-title":"Med Pediatr Oncol."},{"issue":"6","key":"2022040109570001600_CIT0008","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1064::AID-CNCR24>3.0.CO;2-1","article-title":"A phase I\/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas","volume":"86","author":"Allen","year":"1999","journal-title":"Cancer."},{"issue":"5","key":"2022040109570001600_CIT0009","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0360-3016(98)00501-X","article-title":"There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy","volume":"43","author":"Mandell","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2022040109570001600_CIT0010","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0360-3016(02)04391-2","article-title":"A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma","volume":"55","author":"Marcus","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"16","key":"2022040109570001600_CIT0011","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2002.04.109","article-title":"Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the children\u2019s cancer group","volume":"20","author":"Jennings","year":"2002","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022040109570001600_CIT0012","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0959-8049(02)00029-1","article-title":"Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique","volume":"38","author":"Doz","year":"2002","journal-title":"Eur J Cancer."},{"issue":"1","key":"2022040109570001600_CIT0013","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cncr.20741","article-title":"Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98)","volume":"103","author":"Broniscer","year":"2005","journal-title":"Cancer."},{"issue":"3","key":"2022040109570001600_CIT0014","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/neuonc\/noq199","article-title":"A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium","volume":"13","author":"Pollack","year":"2011","journal-title":"Neuro Oncol."},{"issue":"6","key":"2022040109570001600_CIT0015","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1200\/JCO.2000.18.6.1246","article-title":"Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group","volume":"18","author":"Broniscer","year":"2000","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022040109570001600_CIT0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1006360222643","article-title":"Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas","volume":"44","author":"Jakacki","year":"1999","journal-title":"J Neurooncol."},{"issue":"9","key":"2022040109570001600_CIT0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bjc.6600552","article-title":"Treatment of paediatric pontine glioma with oral trophosphamide and etoposide","volume":"87","author":"Wolff","year":"2002","journal-title":"Br J Cancer."},{"issue":"9","key":"2022040109570001600_CIT0018","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/cncr.21403","article-title":"A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas","volume":"104","author":"Packer","year":"2005","journal-title":"Cancer."},{"issue":"5","key":"2022040109570001600_CIT0019","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/pbc.20382","article-title":"Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study","volume":"45","author":"Greenberg","year":"2005","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2022040109570001600_CIT0020","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/cncr.21534","article-title":"Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study","volume":"104","author":"Bernier-Chastagner","year":"2005","journal-title":"Cancer."},{"issue":"2","key":"2022040109570001600_CIT0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pbc.21154","article-title":"Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a children\u2019s oncology group phase II study","volume":"50","author":"Korones","year":"2008","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"2022040109570001600_CIT0022","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00381-006-0083-x","article-title":"Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution","volume":"22","author":"Sandri","year":"2006","journal-title":"Childs Nerv Syst."},{"issue":"1","key":"2022040109570001600_CIT0023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1005874508975","article-title":"High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children\u2019s cancer group","volume":"37","author":"Dunkel","year":"1998","journal-title":"J Neurooncol."},{"issue":"3","key":"2022040109570001600_CIT0024","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<685::AID-CNCR27>3.0.CO;2-K","article-title":"Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas","volume":"88","author":"Bouffet","year":"2000","journal-title":"Cancer."},{"issue":"9","key":"2022040109570001600_CIT0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene."},{"issue":"17","key":"2022040109570001600_CIT0026","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022040109570001600_CIT0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol."},{"issue":"21","key":"2022040109570001600_CIT0028","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022040109570001600_CIT0029","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-007-9337-z","article-title":"Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model","volume":"83","author":"Ugur","year":"2007","journal-title":"J Neurooncol."},{"issue":"1","key":"2022040109570001600_CIT0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2022040109570001600_CIT0031","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2022040109570001600_CIT0032","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1471-4159.2005.03098.x","article-title":"Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo","volume":"93","author":"Ey\u00fcpoglu","year":"2005","journal-title":"J Neurochem."},{"issue":"4","key":"2022040109570001600_CIT0033","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2022040109570001600_CIT0034","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11060-006-9142-0","article-title":"Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma","volume":"79","author":"Spiller","year":"2006","journal-title":"J Neurooncol."},{"issue":"12","key":"2022040109570001600_CIT0035","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022040109570001600_CIT0036","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a children\u2019s oncology group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022040109570001600_CIT0037","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022040109570001600_CIT0038","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials."},{"issue":"4","key":"2022040109570001600_CIT0039","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2307\/2530150","article-title":"Rank tests and a one-sample logrank test for comparing observed survival data to a standard population","volume":"37","author":"Woolson","year":"1981","journal-title":"Biometrics."},{"issue":"282","key":"2022040109570001600_CIT0040","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Amer Statist Assoc"},{"key":"2022040109570001600_CIT0041","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data.","author":"Kalbfleisch","year":"2002"},{"issue":"13-14","key":"2022040109570001600_CIT0042","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/sim.4780131308","article-title":"Interim analysis: the alpha spending function approach","volume":"13","author":"DeMets","year":"1994","journal-title":"Stat Med."},{"issue":"1","key":"2022040109570001600_CIT0043","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-020-00953-2","article-title":"Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients","volume":"8","author":"Guntner","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"11","key":"2022040109570001600_CIT0044","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington\u2019s disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PLoS One."},{"issue":"7","key":"2022040109570001600_CIT0045","doi-asserted-by":"crossref","first-page":"e69964","DOI":"10.1371\/journal.pone.0069964","article-title":"SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition","volume":"8","author":"Hanson","year":"2013","journal-title":"PLoS One."},{"issue":"3","key":"2022040109570001600_CIT0046","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet."},{"issue":"5","key":"2022040109570001600_CIT0047","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat Genet."},{"issue":"6","key":"2022040109570001600_CIT0048","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","article-title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","volume":"130","author":"Castel","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2022040109570001600_CIT0049","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med."},{"issue":"5","key":"2022040109570001600_CIT0050","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab188\/40074102\/noab188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/4\/655\/43218875\/noab188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/4\/655\/43218875\/noab188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:04:38Z","timestamp":1648793078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/4\/655\/6339987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8,4]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab188","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,8,4]]}}}